Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.78B | $1.97B | $2.21B | $2.41B | $2.71B | $3.22B | $3.37B | $3.66B | $3.90B | $4.30B |
| Revenue growth | — | 10.9% | 12.4% | 8.8% | 12.5% | 18.8% | 4.7% | 8.7% | 6.5% | 10.4% |
| Gross profit | $975M | $1.10B | $1.24B | $1.37B | $1.57B | $1.89B | $2.00B | $2.19B | $2.38B | $2.66B |
| Gross margin | 54.9% | 55.7% | 56.1% | 56.7% | 58.0% | 58.8% | 59.5% | 59.8% | 61.0% | 61.8% |
| Operating income | $350M | $413M | $491M | $553M | $695M | $932M | $899M | $1.10B | $1.13B | $1.36B |
| Operating margin | 19.7% | 21.0% | 22.2% | 23.0% | 25.7% | 29.0% | 26.7% | 30.0% | 29.0% | 31.6% |
| Net income | $222M | $263M | $377M | $428M | $582M | $745M | $679M | $845M | $888M | $1.06B |
| Net margin | 12.5% | 13.4% | 17.0% | 17.8% | 21.5% | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% |
| EPS (diluted) | $2.44 | $2.94 | $4.26 | $4.89 | $6.71 | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $339M | $373M | $400M | $459M | $648M | $756M | $543M | $907M | $929M | $1.18B |
| Capital expenditures | $64.8M | $74.4M | $116M | $155M | $107M | $120M | $149M | $134M | $121M | $125M |
| Free cash flow | $274M | $299M | $284M | $304M | $541M | $636M | $394M | $773M | $808M | $1.06B |
| Share buybacks | $304M | $283M | $369M | $302M | $183M | $747M | $820M | $71.9M | $837M | $1.22B |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $155M | $188M | $124M | $90.3M | $384M | $144M | $113M | $454M | $288M | $180M |
| Total assets | $1.53B | $1.71B | $1.54B | $1.83B | $2.29B | $2.44B | $2.75B | $3.26B | $3.29B | $3.35B |
| Total liabilities | $1.64B | $1.77B | $1.55B | $1.65B | $1.66B | $1.75B | $2.14B | $1.78B | $1.70B | $1.75B |
| Long-term debt | $594M | $607M | $602M | $699M | $858M | $775M | $694M | $623M | $450M | $375M |
| Shareholders' equity | -$108M | -$54.1M | -$9.51M | $177M | $632M | $690M | $609M | $1.48B | $1.60B | $1.61B |
| Retained earnings | $540M | $804M | $1.17B | $1.60B | $2.18B | $2.92B | $3.60B | $4.44B | $5.33B | $6.39B |
| Shares (wtd avg diluted) | 90.9M | 89.6M | 88.5M | 87.5M | 86.7M | 86.6M | 84.6M | 84.0M | 83.2M | 81.0M |
Every figure is extracted from IDEXX LABORATORIES INC /DE’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.